Apomate may predict patient's chemotherapy response:
This article was originally published in Clinica
North American Scientific (NAS) has filed an application with the US FDA for permission to continue with studies to evaluate its nuclear imaging agent, Apomate - technetium-labelled annexin V - for assessing a patient's response to chemotherapy. Apomate, developed by NAS' subsidiary Theseus Imaging, targets phosphatidylserine, which is released during cell death. The Chatsworth, California company is currently conducting clinical trials of Apomate for imaging acute myocardial infarction and cardiac transplant rejection.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.